Welcome to our dedicated page for APLI news (Ticker: APLI), a resource for investors and traders seeking the latest updates and insights on APLI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect APLI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of APLI's position in the market.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the Inaugural Emerging Growth Virtual Conference from March 17-19. CEO Dr. Armand Balboni will partake in a Fireside Chat on March 19 at 4:30 PM ET. The presentation is scheduled for March 19 at 2:30 PM ET, with opportunities for one-to-one meetings throughout the conference. Interested investors can register HERE. A replay will be available on Appili’s website after the event.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series focusing on infectious diseases, featuring notable experts like Dr. Scott Gottlieb and Dr. Syra Madad. The first event, scheduled for March 3 at 1:00 p.m. ET, will discuss pandemic response strategies and future infectious outbreaks. This initiative aims to enhance understanding and investment in treatments and public health policies. The company continues to support late-stage clinical trials for its antiviral candidate, highlighting its commitment to addressing urgent healthcare needs.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series on global infectious disease trends, starting on March 3, 2021, featuring prominent speakers including Dr. Scott Gottlieb and Dr. Syra Madad. The panel will focus on pandemic response strategies, treatment investments, and future infectious disease challenges. The event is free and open to the public with prior registration. Appili Therapeutics is actively involved in developing antiviral treatments, including late-stage trials for Avigan® / REEQONUSTM for COVID-19.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the virtual Biocom Global conference from February 23-25, 2021. The presentation will focus on favipiravir, an antiviral therapy approved in Japan for influenza, and its potential use in treating COVID-19, alongside updates on their antifungal compound ATI-2307. The CEO, Armand Balboni, will host one-on-one investor meetings. The event features prominent speakers and highlights the importance of collaboration in addressing patient needs during the pandemic. For more details, visit biocomglobalpartnering.org.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) has announced a new webinar series focused on global infectious disease trends, starting with an event on March 3, featuring Dr. Scott Gottlieb. The series aims to explore challenges in combating COVID-19, including public health policies and new viral strains. The first session will include a Q&A segment and address the necessity for diverse treatments and public health strategies. Additionally, other events will be scheduled throughout the year, promoting ongoing discussions in the infectious disease sector.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) released its financial results for Q3 of FY2021, reporting a net loss of $9.34 million, up from $4.13 million in the same period the previous year. Key operational highlights include a collaboration with Dr. Reddy’s Laboratories to advance the COVID-19 antiviral favipiravir, and the initiation of clinical trials for its PRESECO study. As of December 31, 2020, the company had cash and short-term investments of $20.29 million. Appili remains committed to addressing COVID-19 through its antiviral programs.
Appili Therapeutics has appointed Rochelle Stenzler to its Board of Directors. Stenzler is a seasoned executive with a wealth of experience in healthcare, previously leading companies like TouchLogic Corporation and Revlon Canada. Her expertise in governance and leadership aims to support Appili during a critical phase in its development of favipiravir and other anti-infective programs. Stenzler's background includes significant roles in corporate governance, enhancing the board's capability to drive the company's mission against infectious diseases.
Appili Therapeutics (TSX: APLI, OTCQX: APLIF) announced the recruitment for its Phase 3 PRESECO trial, evaluating favipiravir for early COVID-19 treatment. The trial is currently enrolling participants at 12 of 20 planned sites in the U.S., aiming for an interim data readout by March 2021. Appili is also seeking regulatory approvals to expand the trial into Mexico, Brazil, and Colombia. Favipiravir, an oral antiviral, has shown significant potential in treating mild to moderate COVID-19, and Appili is focusing resources on accelerating recruitment and data analysis.
Appili Therapeutics (TSX: APLI, OTCQX: APLIF) announced that CEO Dr. Armand Balboni will present at HC Wainwright’s inaugural BioConnect 2021 virtual conference from January 11-14, 2021. The pre-recorded presentation will be available on demand starting January 11 at 6:00 AM ET for one week. This conference serves as a forum for companies to connect with investors during the JP Morgan Healthcare Conference. Appili focuses on developing novel therapies for life-threatening infections, including advancing clinical trials for the antiviral Avigan® for COVID-19 treatment.
